Walgreens and BARDA Form Strategic Partnership to Strengthen Decentralized Clinical Trials Model and Reporting

Rhea-AI Summary

Walgreens WBA and BARDA have formed a strategic partnership to enhance decentralized clinical trials (DCTs) in the US. This $100 million, five-year collaboration aims to address barriers in DCT access and conduct trials through the D-COHRe program. Walgreens will leverage its clinical trial ecosystem, which has reached over 5 million potential participants since 2022, consistently meeting recruitment goals and surpassing national averages for diverse participant recruitment.

The partnership seeks to strengthen US decentralized clinical research capabilities, support FDA-regulated product development, and evaluate medical countermeasures for public health emergencies. Walgreens' approach combines its physical footprint with a decentralized platform to engage patients conveniently, positioning it as an ideal partner for enhancing DCTs during public health crises.

Positive

• Strategic partnership with BARDA valued at up to $100 million over five years
• Walgreens' clinical trial ecosystem has reached over 5 million potential participants since 2022
• Consistently meeting recruitment goals and surpassing national averages for diverse participant recruitment
• Positioned as an ideal partner for enhancing decentralized clinical trials during public health emergencies

Negative

• None.

Financial Analyst

The $100 million strategic partnership between Walgreens and BARDA over five years is a significant development for Walgreens' clinical trial business. This collaboration could potentially diversify Walgreens' revenue streams and position the company as a key player in decentralized clinical trials. The partnership addresses a important market need, given that 80% of trials fail to meet enrollment goals, costing billions in delays annually. Walgreens' extensive pharmacy network and proven track record in recruiting diverse participants could lead to increased efficiency and cost savings in clinical trials, potentially boosting the company's bottom line. However, investors should note that this is a long-term initiative and immediate financial impact may be

Medical Research Analyst

This partnership marks a significant shift in clinical trial methodology. Walgreens' ability to reach over 5 million potential participants since 2022 is impressive, potentially accelerating drug development timelines. The focus on decentralized clinical trials (DCTs) aligns with industry trends towards patient-centric research. Walgreens' success in surpassing national averages for recruiting diverse participants addresses a critical issue in clinical research. The collaboration's emphasis on public health emergency preparedness is timely, potentially improving the U.S.'s ability to respond to future health crises. However, the effectiveness of pharmacy-based DCTs in complex trials remains to be seen and regulatory challenges may arise.

Market Research Analyst

This partnership positions Walgreens at the forefront of a growing market. With only 5% of the U.S. population participating in clinical trials, there's significant room for growth. Walgreens' extensive network of community pharmacies provides a unique advantage in accessing diverse populations, potentially disrupting traditional clinical research organizations. The focus on decentralized trials aligns with post-pandemic trends towards remote healthcare solutions. However, competition in this space is likely to intensify and Walgreens will need to demonstrate consistent success to maintain its edge. The partnership's impact on Walgreens' core pharmacy business and potential for cross-selling opportunities should be closely monitored by investors.

This first-of-its-kind collaboration between Walgreens and U.S. government aims to address barriers in decentralized clinical trial access and conduct trials over a five-year period, valued up to $100 million for the D-COHRe program

DEERFIELD, Ill.--(BUSINESS WIRE)-- Walgreens and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), today announced a strategic partnership to increase innovation in decentralized clinical trials as part of the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program. The program is designed to strengthen U.S. decentralized clinical research capabilities to support development of U.S. Food and Drug Administration (FDA)-regulated products, enhance clinical innovation to execute more efficient and relevant clinical research and evaluate other medical countermeasures in real world environments that may be used in a public health emergency.

The partnership will utilize Walgreens’s clinical trial ecosystem, which has proven effective in making clinical trials more accessible and representative of the U.S. population and has reached more than five million patients to potentially recruit into clinical trials since its launch in 2022.

Walgreens is committed to making decentralized clinical research models more efficient and accessible to the U.S. population during their routine healthcare journey and during public health emergencies. Walgreens has consistently met recruitment goals and has continuously surpassed national averages for recruiting diverse clinical trial participants for its sponsor-led clinical trials. Walgreens successfully activates a comprehensive approach to participant recruitment that utilizes its physical footprint and its decentralized clinical trial platform to engage patients and potential patients where it’s most convenient for them. This positions Walgreens as the ideal partner to help enhance decentralized clinical research to validate, pilot and implement new products, technologies and approach for remote and/or decentralized use during a public health emergency, including immunizations, diagnostics, and treatments.

“It is a privilege to continue our partnership with BARDA to strengthen clinical research in the U.S. through a decentralized model in a community pharmacy setting like Walgreens,” said Ramita Tandon, chief clinical trials officer at Walgreens. “Our network of community pharmacies and our compliant and secure clinical trial platform enables us to pioneer a comprehensive solution to make clinical research an integral part of a patient’s healthcare journey, especially when it is most critical for the well-being of our country, during a public health emergency.”

Nearly 80% of trials fail to meet their enrollment goals in the stated timeframes, often contributing to billions of dollars in delays annually. With only 5% of the U.S. population participating in clinical trials, there is a clear need to increase access and representation in clinical research. Walgreens is committed to working with BARDA to help make decentralized clinical trials more accessible and representative of the U.S. population.

Walgreens is also partnering with BARDA on a Phase IV observational COVID-19 trial to enhance U.S. public health preparedness through the Walgreens community pharmacy network.

About Walgreens:

Walgreens (http://www.walgreens.com) is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. True to its purpose of “more joyful lives through better health,” Walgreens has a more than 120-year heritage of caring for communities and providing trusted pharmacy services, and today is playing a greater role as an independent partner of choice offering healthcare services that improve care, lower costs, and help patients. Operating nearly 9,000 retail locations across the U.S. and Puerto Rico, Walgreens is proud to serve nearly 9 million customers and patients daily. The company’s pharmacists are playing a more critical role in healthcare than ever before, providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for some of the nation’s most underserved populations. Walgreens offers customers and patients a true omnichannel experience, with fully integrated physical and digital platforms designed to deliver high-quality products and healthcare services. Within the U.S. Healthcare segment, Walgreens portfolio also includes businesses in primary care, multi-specialty, post-acute care, urgent care, specialty pharmacy services, population health and provider enablement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240819166725/en/

Walgreens

Carmen Lopez

media@walgreens.com

Source: Walgreens

FAQ

What is the value and duration of the partnership between Walgreens (WBA) and BARDA?

The partnership between Walgreens (WBA) and BARDA is valued at up to $100 million over a five-year period for the D-COHRe program.

How many potential participants has Walgreens' (WBA) clinical trial ecosystem reached since 2022?

Walgreens' (WBA) clinical trial ecosystem has reached more than 5 million potential participants since its launch in 2022.

What is the main goal of the Walgreens (WBA) and BARDA partnership?

The main goal is to increase innovation in decentralized clinical trials and strengthen U.S. decentralized clinical research capabilities to support FDA-regulated product development and evaluate medical countermeasures for public health emergencies.

How does Walgreens (WBA) approach participant recruitment for clinical trials?

Walgreens (WBA) uses a comprehensive approach that combines its physical footprint of community pharmacies with a decentralized clinical trial platform to engage patients where it's most convenient for them.